AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
3 reports, 3 independent
Updated Jun 22
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 6
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- M&A activity is driving sector recovery.Sub-event
- The competitive landscape heats up as Sanofi's Dupixent faces challenges from AbbVie's new drug and Zumilokibart.Sub-event
AbbVie is focusing on pipeline growth and alternatives to Dupixent amid drug exclusivity challenges.1 source
AbbVie is leveraging acquisitions, including Apogee Therapeutics, to bolster its next-generation immunology pipeline while competing in the atopic dermatitis market and managing Humira's patent expiry.1 source
AbbVie executes major acquisition of Apogee Therapeutics.1 source
- AbbVie and Eli Lilly are competing in the pharmaceutical market.Sub-event
Keep exploring
The entities involved
Related events
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.